Incyte stock has risen 15.3% in the past year with potential for further growth

From Zacks Investment Research: 2025-01-20 15:36:08

Shares of Incyte (INCY) have risen 15.3% in the past year, outperforming the industry but lagging the S&P 500. The company highlighted at a recent conference that 2025 will be transformational with four potential launches. Incyte’s lead drug, Jakafi, continues to maintain momentum, with strong sales in various indications. The FDA approval of new drugs like Opzelura for atopic dermatitis and Niktimvo for GVHD has been significant. Incyte is also looking to expand its pipeline through strategic acquisitions. While the company is heavily dependent on Jakafi, the potential approval of additional drugs could diversify its portfolio and drive revenue growth. Overall, Incyte is a good stock to buy at current levels, with a Zacks Rank of #2 (Buy).



Read more at Zacks Investment Research: Incyte Gains 15.3% in a Year: Is There Room for Further Growth? – January 20, 2025